resonate: ibrutinib associated with favourable pfs and os in cll
Published 5 years ago • 163 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:56
emerging ibrutinib-based combinations in cll
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:56
resonate-2: ibrutinib and chlorambucil for frontline cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
7:29
venetoclax obinutuzumab: impact on cll management
-
4:34
arthur's story: his cll diagnosis. challenges, treatments and future hope.
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:08
re-analysis of resonate-2 trial of ibrutinib vs chlorambucil in cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:56
resonate-2 trial of ibtrutinib in cll
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
2:00
ibrutinib: use in small cll subgroups only?
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
2:50
venetoclax and ibrutinib based approaches in cll
-
2:18
first-line ibrutinib and venetoclax in cll